AstraZeneca India Roped In Bhavana Agrawal As CFO With Effect From October

AstraZeneca Pharma India has announced the appointment of Bhavana Agrawal as chief finance officer (CFO) with effect from October 1, 2023, following a transition period, according to a company statement issued today. She succeeds Rajesh Marwaha, who will step down as CFO and full-time director of the company on September 30, 2023. Marwaha has been instrumental in developing strategic frameworks for the company in India in tandem with the evolving environment of the country's pharmaceutical sector. As a board member, he has also been a strong anchor behind key initiatives aimed at improving access to healthcare.

"With his extensive and diverse experience across industries, Rajesh has been a valuable asset and guiding light for us." I'd like to thank him for his outstanding leadership and significant contribution to our country's legacy. At the same time, I am delighted to welcome Bhavana at this critical point in our journey of growth through innovation. We are constantly pushing the boundaries of science to deliver life-changing medicines, and I am confident that with her unique global experience, we will be able to accelerate our goal of transforming patient outcomes," said Dr. Sanjeev Panchal, country president of AstraZeneca India.

Agrawal's last role was as CFO of the services business at GE Healthcare for Middle East, Africa & Russia, where she was responsible for revenue, costs, cash, planning session and financial closing activities in more than 30 countries. In her new role, she will oversee the company's financial strategy and operations, planning and analysis, and investor relations. AstraZeneca operates in over 100 countries. AstraZeneca Pharma India was established in 1979 and is headquartered in Bengaluru. It has a workforce of over 800 employees across the country.